S

Senseonics Holdings Inc
AMEX:SENS

Watchlist Manager
Senseonics Holdings Inc
AMEX:SENS
Watchlist
Price: 0.316 USD -2.08% Market Closed
Market Cap: 187.3m USD
Have any thoughts about
Senseonics Holdings Inc?
Write Note

Senseonics Holdings Inc
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Senseonics Holdings Inc
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
S
Senseonics Holdings Inc
AMEX:SENS
Income from Continuing Operations
-$80.3m
CAGR 3-Years
45%
CAGR 5-Years
2%
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Income from Continuing Operations
$1.7B
CAGR 3-Years
2%
CAGR 5-Years
8%
CAGR 10-Years
4%
Boston Scientific Corp
NYSE:BSX
Income from Continuing Operations
$1.8B
CAGR 3-Years
16%
CAGR 5-Years
12%
CAGR 10-Years
20%
Stryker Corp
NYSE:SYK
Income from Continuing Operations
$3.6B
CAGR 3-Years
24%
CAGR 5-Years
14%
CAGR 10-Years
19%
Abbott Laboratories
NYSE:ABT
Income from Continuing Operations
$5.8B
CAGR 3-Years
-7%
CAGR 5-Years
12%
CAGR 10-Years
14%
Intuitive Surgical Inc
NASDAQ:ISRG
Income from Continuing Operations
$2.3B
CAGR 3-Years
10%
CAGR 5-Years
12%
CAGR 10-Years
18%
No Stocks Found

Senseonics Holdings Inc
Glance View

Market Cap
187.3m USD
Industry
Health Care

Senseonics Holdings, Inc. engages in the design, development, and commercialization of an implantable continuous glucose monitoring system for people with diabetes. The company is headquartered in Germantown, Maryland and currently employs 121 full-time employees. The company went IPO on 2015-03-04. The firm is focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community. Its Eversense, Eversense XL, and Eversense E3 continuous glucose monitoring (CGM) systems are designed to continually measure glucose levels in people with diabetes via an under-the-skin sensor, a removable and rechargeable smart transmitter, and a mobile application for real-time diabetes monitoring and management for a period of up to six months. The company is also developing its Gemini product variation to allow for a two-in-one glucose monitoring system combining the functionality of CGM and Flash Glucose Monitoring (FGM), in an implantable sensor that may be utilized with a smart transmitter to get continuous glucose readings and alerts or be utilized through a swipe over the sensor with a smart phone to get on-demand glucose readings without a smart transmitter.

SENS Intrinsic Value
0.139 USD
Overvaluation 56%
Intrinsic Value
Price
S

See Also

What is Senseonics Holdings Inc's Income from Continuing Operations?
Income from Continuing Operations
-80.3m USD

Based on the financial report for Sep 30, 2024, Senseonics Holdings Inc's Income from Continuing Operations amounts to -80.3m USD.

What is Senseonics Holdings Inc's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
2%

Over the last year, the Income from Continuing Operations growth was -154%. The average annual Income from Continuing Operations growth rates for Senseonics Holdings Inc have been 45% over the past three years , 2% over the past five years .

Back to Top